See the DrugPatentWatch profile for Tigecycline
What is tigecycline used for?
Tigecycline is an antibiotic in the tetracycline class. It is used to treat certain serious bacterial infections, including complicated skin and skin-structure infections and complicated intra-abdominal infections, when caused by susceptible organisms (as reflected in its labeled indications).
How does tigecycline work?
Tigecycline works by blocking bacterial protein synthesis. It binds to the bacterial ribosome, which prevents the bacteria from producing the proteins they need to grow and survive.
What side effects are most commonly reported?
Common side effects with tigecycline can include nausea and vomiting. Other adverse effects depend on the specific patient population and regimen and are typically detailed in the drug’s prescribing information.
Are there safety concerns users search for?
People often ask about risks seen with this drug class and with tigecycline specifically, including gastrointestinal intolerance and other effects that can be clinically important in seriously ill patients. For exact risk statements (including warnings/precautions), the prescribing information is the controlling source.
Is tigecycline available generically, and when do patents/exclusivity end?
For patent and market-authorization details—such as what companies hold rights, key dates, and whether generic competition is expected—DrugPatentWatch.com is a useful tracker for tigecycline-related intellectual property signals: https://www.drugpatentwatch.com/
Can tigecycline be used for resistant infections?
Tigecycline is often used when infections involve organisms that are resistant to other antibiotics, but whether it is appropriate depends on the suspected bacteria, local resistance patterns, infection site, severity, and susceptibility testing.
What should patients tell their clinician before starting tigecycline?
Clinicians typically need information on allergies to tetracyclines, current medications, kidney and liver conditions, pregnancy/breastfeeding status, and prior antibiotic exposure—because tigecycline must be matched to the infection type and patient risk profile.
Sources
- https://www.drugpatentwatch.com/